TPMT testing before azathioprine therapy?

Drug and Therapeutics Bulletin

Volumn 47, Issue 1, 2009, Pages 9-12

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOURIC ACID; ALLOPURINOL; AZATHIOPRINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE; METHYLTRANSFERASE;

ANEMIA; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; BONE MARROW TOXICITY; CHOLESTASIS; COST EFFECTIVENESS ANALYSIS; DNA SYNTHESIS; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LIVER FUNCTION TEST; NAUSEA; PANCREATITIS; PATIENT SELECTION; PHARMACOGENETICS; PREVALENCE; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; BONE MARROW DISEASE; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; ECONOMICS; ENZYME ASSAY; METHODOLOGY;

AZATHIOPRINE; BONE MARROW DISEASES; CLINICAL ENZYME TESTS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES;

EID: 66749086530     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.12.0033     Document Type: Review

References (30)

1. Anstey A et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J Royal Soc Med 1992; 85: 752-6.
2. Holme SA et al. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q J Med 2002; 95: 439-44.
3. Cooper SC et al. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 2008; 9: 303-9.
4. Anstey AV et al. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004; 151: 1123-32.
5. Patel AA et al. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89.
6. Imuran Tablets 25mg. Summary of product characteristics. GlaxoSmithKline UK. June 2007, UK.
7. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.
8. Joint Formulary Committee. British National Formulary. Edition 56. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2008.
9. Carter MJ et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (suppl V) V1-16.
10. Gisbert JP et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastronterol 2006; 101: 2769-76.
11. Stolk JN et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arth Rheum 1998 41: 1858-66.
12. Colombel JF et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
13. Evans WE et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
14. Naughton MA et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38: 640-44.
15. Ansari A et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-83.
16. Szumlanski CL et al. Thiopurine methyltransferase pharmacogenetics: human liver enzyme activity. Clin Pharmacol Ther 1988; 43: 134.
17. Szumlanski CL et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2: 148-59.
18. Ford L et al. Whose TPMT is it anyway? Ann Clin Biochem 2004; 41: 498-500.
19. Pathology Department, City Hospital, Dudley Road, Birmingham 2008. Tests: thiopurine methyltransferase service [online]. Available: http://www.cityassays.org.uk/tpmt.html [Accessed 22 December 2008].
20. Fargher EA et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32: 187-95.
21. Black AJ et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
22. Ollier WER. A prospective randomised controlled trial of azathioprine methyltransferase (TPMT) genotyping in the management of patients, prior to commencement of azathioprine. UK Clnical Trials Gateway (Trial completed) [online]. Available: http://www.controlled-trials.com/mrct/trial/238433/ azathioprine [Accessed 22 December 2008].
23. Meggitt SJ et al. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe-atopic eczema: a double-blind randomised controlled trial. Lancet 2006; 367: 839-46.
24. Gardiner SJ et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008; 6: 654-60.
25. Gisbert JP. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53: 399-404.
26. Compagni A et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008; 24: 294-302.
27. Newman W, Payne K. Removing barriers to a clinical pharmacogenetics service. Personalized Med 2008; 5: 471-80.
28. Hilton-Jones D, Palace, J. The management of myasthenia gravis. Pract Neurol 2005; 5: 18-27.
29. Travis SPL et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's and Colitis 2008; 2: 24-62.
30. British Society for Rheumatology. National Guidelines for the monitoring of second line drugs. July 2000.